Multimodal patient blood management program based on a three-pillar strategy: a systematic review and meta-analysis. (отваря нов прозорец)

Althoff FC, Neb H, Herrmann E, Trentino KM, Vernich L, Füllenbach C, Freedman J, Waters JH, Farmer S, Leahy MF, Zacharowski K, Meybohm P, Choorapoikayil S

Източник‎: Ann Surg 2019;269(5):794-804.

Статията е индексирана‎: PubMed 30418206

DOI‎: 10.1097/SLA.0000000000003095

https://www.ncbi.nlm.nih.gov/pubmed/30418206 (отваря нов прозорец)

Saving blood and reducing costs: updating blood transfusion practice in lower limb arthroplasty. (отваря нов прозорец)

Fenelon C, Galbraith JG, Kearsley R, Motherway C, Condon F, Lenehan B.

Източник‎: Ir Med J 2018;111(4):730.

Статията е индексирана‎: PubMed 30465599

https://www.ncbi.nlm.nih.gov/pubmed/30465599 (отваря нов прозорец)

Effect of a patient blood management programme on preoperative anaemia, transfusion rate, and outcome after primary hip or knee arthroplasty: a quality improvement cycle. (отваря нов прозорец)

Kotzé A, Carter LA, Scally AJ.

Източник‎: Br J Anaesth 2012;108(6):943-52.

Статията е индексирана‎: PubMed 22593128

DOI‎: 10.1093/bja/aes135

https://www.ncbi.nlm.nih.gov/pubmed/22593128 (отваря нов прозорец)

Cost of post-operative intravenous iron therapy in total lower limb arthroplasty: a retrospective, matched cohort study. (отваря нов прозорец)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Naveira E, Seara J, Pavía J.

Източник‎: Blood Transfus 2014;12(1):40-9.

Статията е индексирана‎: PubMed 24120595

DOI‎: 10.2450/2013.0088-13

https://www.ncbi.nlm.nih.gov/pubmed/24120595 (отваря нов прозорец)

Improved patient blood management and cost saving in hip replacement surgery through the implementation of pre-operative Sucrosomial® iron supplementation: a quality improvement assessment study. (отваря нов прозорец)

Scardino M, Di Matteo B, Martorelli F, Tanzi D, Kon E, D'Amato T.

Източник‎: Int Orthop 2019;43(1):39-46.

Статията е индексирана‎: PubMed 30232527

DOI‎: 10.1007/s00264-018-4149-7

https://www.ncbi.nlm.nih.gov/pubmed/30232527 (отваря нов прозорец)

Clinical and budget impact of treating preoperative anemia in major orthopedic surgery--a retrospective observational study. (отваря нов прозорец)

Wan S, Sparring V, Cabrales DA, Jansson KÅ, Wikman A.

Източник‎: J Arthroplasty 2020;35(11):3084-8.

Статията е индексирана‎: PubMed 32654943

DOI‎: 10.1016/j.arth.2020.06.018

https://www.ncbi.nlm.nih.gov/pubmed/32654943 (отваря нов прозорец)

Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlled trial (TRANX-H). (отваря нов прозорец)

Alshryda S, Mason J, Sarda P, Nargol A, Cooke N, Ahmad H, Tang S, Logishetty R, Vaghela M, McPartlin L, Hungin AP.

Източник‎: J Bone Joint Surg Am 2013;95(21):1969-74.

Статията е индексирана‎: PubMed 24196467

DOI‎: 10.2106/JBJS.L.00908

https://www.ncbi.nlm.nih.gov/pubmed/24196467 (отваря нов прозорец)

Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: a randomized controlled trial (TRANX-K). (отваря нов прозорец)

Alshryda S, Mason J, Vaghela M, Sarda P, Nargol A, Maheswaran S, Tulloch C, Anand S, Logishetty R, Stothart B, Hungin AP.

Източник‎: J Bone Joint Surg Am 2013;95(21):1961-8.

Статията е индексирана‎: PubMed 24196466

DOI‎: 10.2106/JBJS.L.00907

https://www.ncbi.nlm.nih.gov/pubmed/24196466 (отваря нов прозорец)

Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery. (отваря нов прозорец)

Berenholtz SM, Pham JC, Garrett-Mayer E, Atchison CW, Kostuik JP, Cohen DB, Nundy S, Dorman T, Ness PM, Klag MJ, Pronovost PJ, Kebaish KM.

Източник‎: Spine 2009;34(19):2096-103.

Статията е индексирана‎: PubMed 19730217

DOI‎: 10.1097/BRS.0b013e3181b1fab2

https://www.ncbi.nlm.nih.gov/pubmed/19730217 (отваря нов прозорец)

The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty. (отваря нов прозорец)

Cankaya D, Dasar U, Satilmis AB, Basaran SH, Akkaya M, Bozkurt M.

Източник‎: J Orthop Surg 2017;25(1):2309499016684725.

Статията е индексирана‎: PubMed 28176599

DOI‎: 10.1177/2309499016684725

https://www.ncbi.nlm.nih.gov/pubmed/28176599 (отваря нов прозорец)

An evaluation of the use of topical tranexamic acid in total knee arthroplasty. (отваря нов прозорец)

Chimento GF, Huff T, Ochsner JL Jr, Meyer M, Brandner L, Babin S.

Източник‎: J Arthroplasty 2013;28(8 Suppl):74-7.

Статията е индексирана‎: PubMed 24034510

DOI‎: 10.1016/j.arth.2013.06.037

https://www.ncbi.nlm.nih.gov/pubmed/24034510 (отваря нов прозорец)

Hemostatic techniques reduce hospital stay following multilevel posterior cervical spine surgery. (отваря нов прозорец)

Cho SK, Yi JS, Park MS, Hu G, Zebala LP, Pahys JM, Kang MM, Lee DH, Riew KD.

Източник‎: J Bone Joint Surg Am 2012;94(21):1952-8.

Статията е индексирана‎: PubMed 23138237

DOI‎: 10.2106/JBJS.K.00632

https://www.ncbi.nlm.nih.gov/pubmed/23138237 (отваря нов прозорец)

Comparing ε-aminocaproic acid and tranexamic acid in reducing postoperative transfusions in total knee arthroplasty. (отваря нов прозорец)

Churchill JL, Puca KE, Meyer E, Carleton M, Anderson MJ.

Източник‎: J Knee Surg 2017;30(5):460-6.

Статията е индексирана‎: PubMed 27699724

DOI‎: 10.1055/s-0036-1593362

https://www.ncbi.nlm.nih.gov/pubmed/27699724 (отваря нов прозорец)

Process improvement project using tranexamic acid is cost-effective in reducing blood loss and transfusions after total hip and total knee arthroplasty. (отваря нов прозорец)

Demos HA, Lin ZX, Barfield WR, Wilson SH, Robertson DC, Pellegrini VD Jr.

Източник‎: J Arthroplasty 2017;32(8):2375-80.

Статията е индексирана‎: PubMed 28343823

DOI‎: 10.1016/j.arth.2017.02.068

https://www.ncbi.nlm.nih.gov/pubmed/28343823 (отваря нов прозорец)

Comparing cost, efficacy, and safety of intravenous and topical tranexamic acid in total hip and knee arthroplasty. (отваря нов прозорец)

DiBlasi JF, Smith RP, Garavaglia J, Quedado J, Frye BM, Dietz MJ.

Източник‎: Am J Orthop 2016;45(7):E439-43.

Статията е индексирана‎: PubMed 28005108

https://www.ncbi.nlm.nih.gov/pubmed/28005108 (отваря нов прозорец)

Effect of tranexamic acid on transfusion rates following total joint arthroplasty: a cost and comparative effectiveness analysis. (отваря нов прозорец)

Evangelista PJ, Aversano MW, Koli E, Hutzler L, Inneh I, Bosco J, Iorio R.

Източник‎: Orthop Clin North Am 2017;48(2):109-15.

Статията е индексирана‎: PubMed 28336035

DOI‎: 10.1016/j.ocl.2016.12.001

https://www.ncbi.nlm.nih.gov/pubmed/28336035 (отваря нов прозорец)

Tranexamic acid decreases blood loss after total shoulder arthroplasty. (отваря нов прозорец)

Friedman RJ, Gordon E, Butler RB, Mock L, Dumas B.

Източник‎: J Shoulder Elbow Surg 2016;25(4):614-8.

Статията е индексирана‎: PubMed 26652697

DOI‎: 10.1016/j.jse.2015.09.014

https://www.ncbi.nlm.nih.gov/pubmed/26652697 (отваря нов прозорец)

Tranexamic acid in patients with cancer undergoing endoprosthetic reconstruction: a cost analysis. (отваря нов прозорец)

Haase DR, Kimbrel B, Bombardier B, Templeton KJ, Rosenthal HG, Sweeney KR.

Източник‎: J Am Acad Orthop Surg 2021;29(22):961-9.

Статията е индексирана‎: PubMed 34570739

DOI‎: 10.5435/JAAOS-D-20-00971

https://www.ncbi.nlm.nih.gov/pubmed/34570739 (отваря нов прозорец)

Topically applied epsilon-aminocaproic acid reduces blood loss and length of hospital stay after total knee arthroplasty. (отваря нов прозорец)

Harper RA, Sucher MG, Giordani M, Nedopil AJ.

Източник‎: Orthopedics 2017;40(6):e1044-9.

Статията е индексирана‎: PubMed 28968480

DOI‎: 10.3928/01477447-20170925-07

https://www.ncbi.nlm.nih.gov/pubmed/28968480 (отваря нов прозорец)

Does tranexamic acid reduce blood transfusion cost for primary total hip arthroplasty? A case-control study. (отваря нов прозорец)

Harris RN, Moskal JT, Capps SG.

Източник‎: J Arthroplasty 2015;30(2):192-5.

Статията е индексирана‎: PubMed 25534861

DOI‎: 10.1016/j.arth.2014.08.020

https://www.ncbi.nlm.nih.gov/pubmed/25534861 (отваря нов прозорец)

Tranexamic acid reduces blood loss and financial cost in primary total hip and knee replacement surgery. (отваря нов прозорец)

Irisson E, Hémon Y, Pauly V, Parratte S, Argenson JN, Kerbaul F.

Източник‎: Orthop Traumatol Surg Res 2012;98(5):477-83.

Статията е индексирана‎: PubMed 22854336

DOI‎: 10.1016/j.otsr.2012.05.002

https://www.ncbi.nlm.nih.gov/pubmed/22854336 (отваря нов прозорец)

Using tranexamic acid for an additional 24 hours postoperatively in hip and knee arthroplasty saves money: a cost analysis from the TRAC-24 randomized control trial. (отваря нов прозорец)

Karayiannis PN, Agus A, Bryce L, Hill JC, Beverland D.

Източник‎: Bone Jt Open 2022;3(7):536-42.

Статията е индексирана‎: PubMed 35816170

DOI‎: 10.1302/2633-1462.37.BJO-2021-0213.R1

https://www.ncbi.nlm.nih.gov/pubmed/35816170 (отваря нов прозорец)

Cost-benefit analysis of the use of tranexamic acid in total replacement hip surgery. (отваря нов прозорец)

Lopez-Picado A, Barrachina B, Remón M, Errea M.

Източник‎: J Clin Anesth 2019;57:124-8.

Статията е индексирана‎: PubMed 30999196

DOI‎: 10.1016/j.jclinane.2019.04.006

https://www.ncbi.nlm.nih.gov/pubmed/30999196 (отваря нов прозорец)

Transfusion cost savings with tranexamic acid in primary total knee arthroplasty from 2009 to 2012. (отваря нов прозорец)

Moskal JT, Harris RN, Capps SG.

Източник‎: J Arthroplasty 2015;30(3):365-8.

Статията е индексирана‎: PubMed 25458093

DOI‎: 10.1016/j.arth.2014.10.008

https://www.ncbi.nlm.nih.gov/pubmed/25458093 (отваря нов прозорец)

The efficacy, safety, and cost-effectives of combined administration of intravenous and local tranexamic acid in the management of patients undergoing primary total hip arthroplasty: a prospective, blinded and randomized clinical study. (отваря нов прозорец)

Örs Ç, Çaylak R.

Източник‎: Acta Orthop Traumatol Turc 2021;55(5):422-7.

Статията е индексирана‎: PubMed 34730529

DOI‎: 10.5152/j.aott.2021.20397

https://www.ncbi.nlm.nih.gov/pubmed/34730529 (отваря нов прозорец)

Cost analysis of tranexamic acid in anemic total joint arthroplasty patients. (отваря нов прозорец)

Phan DL, Ani F, Schwarzkopf R.

Източник‎: J Arthroplasty 2016;31(3):579-82.

Статията е индексирана‎: PubMed 26601635

DOI‎: 10.1016/j.arth.2015.10.001

https://www.ncbi.nlm.nih.gov/pubmed/26601635 (отваря нов прозорец)

Intravenous administration of tranexamic acid effectively reduces blood loss in primary total knee arthroplasty in a 610-patient consecutive case series. (отваря нов прозорец)

Pitta M, Zawadsky M, Verstraete R, Rubinstein A.

Източник‎: Transfusion 2016;56(2):466-71.

Статията е индексирана‎: PubMed 26509250

DOI‎: 10.1111/trf.13354

https://www.ncbi.nlm.nih.gov/pubmed/26509250 (отваря нов прозорец)

Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. (отваря нов прозорец)

Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, Boettner F, Memtsoudis SG.

Източник‎: BMJ 2014;349:g4829.

Статията е индексирана‎: PubMed 25116268

DOI‎: 10.1136/bmj.g4829

https://www.ncbi.nlm.nih.gov/pubmed/25116268 (отваря нов прозорец)

One intraoperative dose of tranexamic acid for patients having primary hip or knee arthroplasty. (отваря нов прозорец)

Ralley FE, Berta D, Binns V, Howard J, Naudie DD.

Източник‎: Clin Orthop Relat Res 2010;468(7):1905-11.

Статията е индексирана‎: PubMed 20063079

DOI‎: 10.1007/s11999-009-1217-8

https://www.ncbi.nlm.nih.gov/pubmed/20063079 (отваря нов прозорец)

Pharmacologic hemostatic agents in total joint arthroplasty--a cost-effectiveness analysis. (отваря нов прозорец)

Ramkumar DB, Ramkumar N, Tapp SJ, Moschetti WE.

Източник‎: J Arthroplasty 2018;33(7):2092-9.e9.

Статията е индексирана‎: PubMed 29605152

DOI‎: 10.1016/j.arth.2018.02.068

https://www.ncbi.nlm.nih.gov/pubmed/29605152 (отваря нов прозорец)

Use of a fibrin sealant within a blood-saving protocol in patients undergoing revision hip arthroplasty: effects on post-operative blood transfusion and healthcare-related cost analysis. (отваря нов прозорец)

Scardino M, Martorelli F, D'Amato T, Fenocchio G, Simili V, Grappiolo G, Di Matteo B, Kon E, Lagioia M

Източник‎: Int Orthop 2019;43(12):2707-14.

Статията е индексирана‎: PubMed 30671601

DOI‎: 10.1007/s00264-019-04291-4

https://www.ncbi.nlm.nih.gov/pubmed/30671601 (отваря нов прозорец)

Cost benefit analysis of topical tranexamic acid in primary total hip and knee arthroplasty. (отваря нов прозорец)

Tuttle JR, Ritterman SA, Cassidy DB, Anazonwu WA, Froehlich JA, Rubin LE.

Източник‎: J Arthroplasty 2014;29(8):1512-5.

Статията е индексирана‎: PubMed 24630599

DOI‎: 10.1016/j.arth.2014.01.031

https://www.ncbi.nlm.nih.gov/pubmed/24630599 (отваря нов прозорец)

Blood loss and cost-effectiveness of oral vs intravenous tranexamic acid in primary total hip arthroplasty: a randomized clinical trial. (отваря нов прозорец)

Wu Y, Zeng Y, Hu Q, Li M, Bao X, Zhong J, Shen B.

Източник‎: Thromb Res 2018;171:143-8.

Статията е индексирана‎: PubMed 30312799

DOI‎: 10.1016/j.thromres.2018.10.006

https://www.ncbi.nlm.nih.gov/pubmed/30312799 (отваря нов прозорец)

Efficacy and safety of tranexamic acid in total hip replacement: a PRISMA-compliant meta-analysis of 25 randomized controlled trials. (отваря нов прозорец)

Zhu J, Zhu Y, Lei P, Zeng M, Su W, Hu Y.

Източник‎: Medicine 2017;96(52):e9552.

Статията е индексирана‎: PubMed 29384974

DOI‎: 10.1097/MD.0000000000009552

https://www.ncbi.nlm.nih.gov/pubmed/29384974 (отваря нов прозорец)

The safety, efficacy, and cost-effectiveness of intraoperative cell salvage in metastatic spine tumor surgery. (отваря нов прозорец)

Elmalky M, Yasin N, Rodrigues-Pinto R, Stephenson J, Carroll C, Smurthwaite G, Verma R, Mohammad S, Siddique I.

Източник‎: Spine J 2017;17(7):977-82.

Статията е индексирана‎: PubMed 28323241

DOI‎: 10.1016/j.spinee.2017.03.004

https://www.ncbi.nlm.nih.gov/pubmed/28323241 (отваря нов прозорец)

Radiofrequency bipolar hemostatic sealer reduces blood loss, transfusion requirements, and cost for patients undergoing multilevel spinal fusion surgery: a case control study. (отваря нов прозорец)

Frank SM, Wasey JO, Dwyer IM, Gokaslan ZL, Ness PM, Kebaish KM.

Източник‎: J Orthop Surg Res 2014;9:50.

Статията е индексирана‎: PubMed 24997589

DOI‎: 10.1186/s13018-014-0050-2

https://www.ncbi.nlm.nih.gov/pubmed/24997589 (отваря нов прозорец)

Restrictive versus liberal red blood cell transfusion strategy after hip surgery: a decision model analysis of healthcare costs. (отваря нов прозорец)

Fusaro MV, Nielsen ND, Nielsen A, Fontaine MJ, Hess JR, Reed RM, DeLisle S, Netzer G.

Източник‎: Transfusion 2017;57(2):357-66.

Статията е индексирана‎: PubMed 28019009

DOI‎: 10.1111/trf.13936

https://www.ncbi.nlm.nih.gov/pubmed/28019009 (отваря нов прозорец)

Cell saver for adult spinal deformity surgery reduces cost. (отваря нов прозорец)

Gum JL, Carreon LY, Kelly MP, Hostin R, Robinson C, Burton DC, Polly DW, Shaffrey CI, LaFage V, Schwab FJ, Ames CP, Kim HJ, Smith JS, Bess RS; International Spine Study Group.

Източник‎: Spine Deform 2017;5(4):272-6.

Статията е индексирана‎: PubMed 28622903

DOI‎: 10.1016/j.jspd.2017.01.005

https://www.ncbi.nlm.nih.gov/pubmed/28622903 (отваря нов прозорец)